Literature DB >> 33131540

Endocrine Health in Childhood Cancer Survivors.

Hanneke M van Santen1, Wassim Chemaitilly2, Lillian R Meacham3, Emily S Tonorezos4, Sogol Mostoufi-Moab5.   

Abstract

Endocrine late effects, including reproductive disorders and secondary thyroid cancer, have been reported in up to 50 %childhood cancer survivors (CCS) more than 5 years after treatment. Most endocrine disorders are amenable to treatment; awareness of symptoms is therefore of great importance. Recognition of these symptoms may be delayed however because many are nonspecific. Timely treatment of endocrine disorders improves quality of life in CCS and prevents possible consequences, such as short stature, bone and cardiovascular disorders, and depression. At-risk CCS must therefore be regularly and systematically monitored. This article provides a summary of the most commonly reported endocrine late effects in CCS.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone health; Childhood cancer survivor; Growth hormone deficiency; Hypothyroidism; Late effects; Metabolic syndrome; Radiation effects; Secondary thyroid cancer

Year:  2020        PMID: 33131540     DOI: 10.1016/j.pcl.2020.08.002

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  3 in total

1.  Influencing factors of depressive symptoms in patients with malignant tumour.

Authors:  Dongmei Wang; Nana He; Yuwu Liu; Rui Pang; Meikereayi Dilixiati; Ainiwaer Wumaier
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

2.  Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors.

Authors:  Agostino Milluzzo; Lucia Manuella; Emanuela Cannata; Giovanna Russo; Sandro La Vignera; Francesco Purrello; Andrea Di Cataldo; Laura Sciacca
Journal:  J Clin Med       Date:  2022-02-07       Impact factor: 4.241

Review 3.  Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Authors:  Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen
Journal:  Pituitary       Date:  2021-07-25       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.